Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.

Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing therapy rocatinlimab in atopic dermatitis (AD). The 24-week IGNITE study, which ...

Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced new results from the ongoing ROCKET phase 3 clinical trial programme evaluating rocatinlimab, an investigational T-cell rebalancing therapy ...